Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-05-31
2011-05-31
Audet, Maury (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S001690, C514S002600
Reexamination Certificate
active
07951774
ABSTRACT:
Stereochemically defined dipeptide esters of nucleoside-analogous antiviral agents including acyclovir and ganciclovir are provided. Certain of these stereochemically defined dipeptide esters are found to have unexpectedly enhanced delivery to and uptake by ocular tissues, crossing the blood-ocular barrier more effectively than other stereochemically defined dipeptide esters. For example, (L-Val)-(D-Val)-acyclovir was found to be taken up more effectively into corneal tissue than were underivatized acyclovir, monoesters (L-Val)-acyclovir or (D-Val)-acyclovir, or diester (L-Val)-(L-Val)-acyclovir.
REFERENCES:
patent: 5405850 (1995-04-01), Blumenkopf
patent: 7214663 (2007-05-01), Bebbington et al.
patent: 7214664 (2007-05-01), Mitra et al.
patent: 7553812 (2009-06-01), Mitra
patent: 2005/0043246 (2005-02-01), Mitra
patent: 2006/0135438 (2006-06-01), Mitra et al.
patent: 2007/0142302 (2007-06-01), Mitra et al.
patent: 2009/0082566 (2009-03-01), Mitra
patent: 2009/0149482 (2009-06-01), Mitra et al.
patent: WO-03/048190 (2003-06-01), None
“U.S. Appl. No. 10/854,533 response to Final Office Action mailed Nov. 1, 2007”, 19 pgs.
“U.S. Appl. No. 10/854,533, Final Office Action mailed Nov. 1, 2007”, 8 pgs.
“U.S. Appl. No. 10/854,533, Non-Final Office Action mailed Sep. 8, 2006”, 6 pgs.
“U.S. Appl. No. 10/854,533, Response filed Dec. 1, 2006 to Non-Final Office Action mailed Sep. 8, 2006”, 9 pgs.
“U.S. Appl. No. 10/854,533, Response filed Mar. 28, 2007 to Restriction Requirement mailed Feb. 26, 2007”, 8 pgs.
“U.S. Appl. No. 10/854,533, Response filed Jun. 27, 2007 to Non-Final Office Action mailed Feb. 26, 2007”, 8 pgs.
“U.S. Appl. No. 10/854,533, Response filed Jun. 30, 2006 to Restriction Requirement mailed May 16, 2006”, 2 pgs.
“U.S. Appl. No. 10/854,533, Restriction Requirement mailed Feb. 26, 2007”, 7 pgs.
“U.S. Appl. No. 10/854,533, Restriction Requirement mailed May 16, 2006”, 9 pgs.
“U.S. Appl. No. 11/285,754, Non-Final Office Action mailed Jul. 25, 2006”, 8 pgs.
“U.S. Appl. No. 11/285,754, Notice of Allowance mailed Dec. 26, 2006”, 5 pgs.
“U.S. Appl. No. 11/285,754, Preliminary Amendment filed Feb. 8, 2006”, 3 pgs.
“U.S. Appl. No. 11/285,754, Response filed Nov. 21, 2006 to Non-Final Office Action mailed Jul. 25, 2006”, 10 pgs.
“U.S. Appl. No. 11/285,754, Response filed Jun. 20, 2006 to Restriction Requirement mailed May 26, 2006”, 2 pgs.
“U.S. Appl. No. 11/285,754, Restriction Requirement mailed May 26, 2006”, 7 pgs.
“U.S. Appl. No. 11/677,947, Non-Final Office Action mailed Nov. 7, 2008”, 8 pgs.
“International Application Serial No. PCT/US02/338846, International Preliminary Examination Report Dec. 20, 2004”, 6 pgs.
“International Application Serial No. PCT/US02/338846, International Search Report Jul. 21, 2003”, 5 pgs.
“U.S. Appl. No. 10/854,533 Notice of Allowance mailed Jul. 3, 2008.”, NOAR, 11 pgs.
Colla, Leon, et al., “Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]”,Journal of Medicinal Chemistry, 26(4), (Apr. 1983), 602-4.
Dey, Surajit, et al., “Molecular Evidence and Functional Expression of P-Glycoprotein (MDR1) in Human and Rabbit Cornea and Corneal Epithelial Cell Lines ”,Investigative Ophthalmology&Visival Science, 44(7), (Jul. 2003), 2909-2918.
Fricker, Gert, et al., “Modulation of Drug Transporters at the Blood-Brain Barrier”,Pharmacology, 70(4), (2004), 170-176.
Gao, Hongwu, et al., “Regioselective synthesis of various prodrugs of ganciclovir”,Tetrahedron Letters, 41(8), (2000), 1131-1136.
Gaucher, Berandere, “Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity”,Org Biomol Chem., 2(3), (2004), 345-57.
Han, H., “5′-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT Are Absorbed by the Intestinal PEPT1 Peptide Transporter”,Pharmaceutical Research, 15, (1998), 1154-1159.
Irvine, Jennifer D., et al., “MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening”,Journal of Pharamaceutical Sciences, 88(1), (Jan. 1999), 28-33.
Jain, R., et al., “Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization”,Molecular Pharmaceutics, 1(4), (Jul.-Aug. 2004), 290-299.
Jain, Ritesh, et al., “Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification”,International Journal of Pharmaceutics, 303(1-2), (2005), 8-19.
Lee, Vincent H., “Membrane transporters”,European Journal of Pharmaceutical Science, 11(Suppl 2), (Oct. 2000), S41-50.
Rouquayrol, Marielle, et al., “Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers”,Pharmacuetical Research, 19(11), (Nov. 2002), 1704-1712.
Vierling, Pierre, et al., “Prodrugs of HIV Protease Inhibitors”,Current Pharmaceutical Design, 9(22), (2003), 1755-1770.
Mitra Ashim K.
Samanta Swapan K.
Talluri Ravi S.
Audet Maury
Stinson Morrison & Hecker LLP
The Curators of the University of Missouri
LandOfFree
Stereochemically defined dipeptide esters of antiviral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stereochemically defined dipeptide esters of antiviral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stereochemically defined dipeptide esters of antiviral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2700619